Kaneko et al. Tocilizumab leads to significantly lower steroid doses in Adult onset Stills Disease @RheumNow #ACR22 Abstr#0826 https://t.co/jc1S6sdfkm https://t.co/z0cHB4wYu6

• Treatment Pattern and Changes in Oral Glucocorticoid Dose After Tocilizumab Tre…

#ACR22 Abstr#0783. Rituximab impacts on humoral immunity. Our study on 400 RMD pts showed: Breakthrough infection 30% mostly mild; Severe 4%; 1 death Poor outcomes predicted by comorbidities & low IgG Risk reduced by 50% with each vac dose OK for RTX if vaccinated @RheumNow https://t.co/xyJsukm1Rh

Song et al. Korean study shows better persistence of tocilizumab than TNFi as first-line biologic in RA. No difference in incidence of TB. @RheumNow #ACR22 Abstr#0887 https://t.co/EuQkfDZd77 https://t.co/VxJmKEzAVY

• Comparison of Drug Persistence and Incidence of Tuberculosis Between Tumor Necr…

Trend of reduced opioid use when initiating biologics and JAKi in RA though effect size small and very high baseline use (>50%) in this insurance claims database. Residual pain and harm minimisation still areas of need. @RheumNow #ACR22 ABST0925 https://t.co/XGHu0fIMF0 https://t.co/PutNNQiKnY

• Impact of Initiating Biologic and Targeted Synthetic Disease-Modifying Antirheu…

Interesting findings from Abs 0417 - when early axSpA is defined by duration of symptoms, only nr-axSpA tx w/ bDMARDs may lead to better outcomes vs early or established axSpA. #ACR22 @RheumNow https://t.co/8aGdyJRvv1 https://t.co/chAEGPicPd

• Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Lit…

2022 ASAS-EULAR Recommendations of AxSpA management 1) NSAIDs still first line 2) Analgesics/opioids contraindicated 3) TNFi, IL-17i first line bDMARDs, followed by JAKinibs 4) Tapering but not discontinuation of bDMARDs in sustained remission Abs#0542 @RheumNow #ACR22 https://t.co/ffaN2fMc3v

Terrier @TerrierBen . Pooled analysis of MAINRITSAN trials. For major relapse at 84 months RTX>AZA HR 2.5. RTX fixed-dose>tailored HR 3. RTX 18 vs 36 months equal HR 1.2 (although 78% vs 70% relapse free). @RheumNow #ACR22 Abstr#0527 https://t.co/IWQmcGeRiW

• Rituximab as Maintenance Therapy for ANCA-associated Vasculitides: Pooled Analy…

Vikse et al. Norwegian case series of 40 patients treated with RTX for IgG4-RD. Efficacy across phenotypes 80-100% for improvement but only 45-78% for remission. @rheumnow #ACR22 Abstr#0147 https://t.co/J7b47ywbt0 https://t.co/pfhOIG5qXk

• Rituximab in IgG4-Related Diseae: An Open-Label Non-Randomized Observational St…